Medpace (NASDAQ:MEDP) CEO August Troendle Sells 15,609 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 15,609 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.47, for a total transaction of $9,466,390.23. Following the transaction, the chief executive officer owned 588,369 shares of the company’s stock, valued at approximately $356,828,147.43. This represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Trading Up 1.3%

NASDAQ MEDP traded up $8.11 on Friday, hitting $620.75. 225,439 shares of the company’s stock were exchanged, compared to its average volume of 347,887. The stock has a 50-day moving average of $547.09 and a 200-day moving average of $491.80. The stock has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a P/E/G ratio of 2.71 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the company posted $3.10 EPS. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Trading of Medpace

A number of hedge funds have recently made changes to their positions in MEDP. Johnson Financial Group Inc. acquired a new position in shares of Medpace in the second quarter valued at approximately $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Medpace during the 4th quarter worth approximately $30,000. Jones Financial Companies Lllp acquired a new stake in Medpace during the 2nd quarter worth approximately $30,000. Finally, Allied Private Wealth LLC bought a new stake in Medpace during the 2nd quarter worth approximately $31,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Royal Bank Of Canada increased their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and lifted their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Robert W. Baird increased their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Finally, TD Cowen raised their target price on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.